Features of the mucous barrier in functional bowel diseases and ulcerative colitis





mucosal barrier of the bowel, functional bowel di­sease, irritable bowel syndrome, nonspecific ulcerative colitis


Background. The intestinal mucosal barrier may change under the influence of exogenous and endogenous factors. Changes in its physical and chemical characteristics are observed in patients with gastrointestinal diseases, such as irritable bowel syndrome, ulcerative colitis, Crohn’s disease, and with other pathologies, such as diabetes mellitus, food allergies, rheumatoid arthritis, etc. Also, the permeability of the intestinal wall was influenced by tight junctions, which are weakened due to eating disorders, psycho-emotional factors, and chemical agents. The purpose of the study was evaluating of changes in the mucosal barrier in patients with functional and inflammatory bowel diseases. Materials and methods. 270 patients with different subtypes of irritable bowel syndrome and 218 patients with ulcerative colitis were examined. Colonoscopy followed by a morphological assessment of biopsy specimens and immunohistochemical studies using markers of claudin 1 and 7, mucins 1, 2, 3, 4, 5AC, and trefoil factors 1–3 was performed in all patients. Results. A decrease in the level of tight junction proteins called claudins was observed in patients with functional bowel disease. Patients with irritable bowel syndrome associated with diarrhea had a lower level of claudin-1 only, while patients with mixed form had also a lower level of claudin-7. A decrease in the level of both secretory and membrane-bound mucins and an increase in the level of the trefoil factors were observed at the same time among the patients with ulcerative colitis which may indicate a dysregulation and a violation of the protective function of mucus. Conclusions. The pathogenesis of a violation of the protective function of the mucosa of functional and inflammatory bowel disease is different, which may determine approaches to the treatment of patients with such pathologies.


Download data is not yet available.


Bashashati M, Moossavi S, Cremon C, et al. Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil. 2018 Jan;30(1). doi:10.1111/nmo.13192.

Camilleri M, Bueno L, Andresen V, De Ponti F, Choi MG, Lembo A. Pharmacological, pharmacokinetic and pharmacogenomic aspects of functional gastrointestinal disorders. Gastroenterology. 2016 Feb 18:S0016-5085(16)00220-1. doi:10.1053/j.gastro.2016.02.029.

Leech B, Schloss J, Steel A. Treatment interventions for the management of intestinal permeability: a cross-sectional survey of complementary and integrative medicine practitioners. J Altern Complement Med. 2019 Jun;25(6):623-636. doi:10.1089/acm.2018.0374.

Farré R, Vicario M. Abnormal barrier function in gastrointestinal disorders. Handb Exp Pharmacol. 2017;239:193-217. doi:10.1007/164_2016_107.

Zihni C, Mills C, Matter K, Balda MS. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol. 2016 Sep;17(9):564-580. doi:10.1038/nrm.2016.80.

Park MY, Kim MY, Seo YR, Kim JS, Sung MK. High-fat Diet Accelerates Intestinal Tumorigenesis Through Disrupting Intestinal Cell Membrane Integrity. J Cancer Prev. 2016 Jun;21(2):95-103. doi:10.15430/JCP.2016.21.2.95.

Simrén M, Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat Rev Gastroenterol Hepatol. 2018 Oct;15(10):589-605. doi:10.1038/s41575-018-0034-5.

Enck P, Mazurak N. Dysbiosis in functional bowel disorders. Ann Nutr Metab. 2018;72(4):296-306. doi:10.1159/000488773.

Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol. 2007 Apr;38(4):564-569. doi:10.1016/j.humpath.2006.11.007.

Tsukita S, Tanaka H, Tamura A. The claudins: from tight junctions to biological systems. Trends Biochem Sci. 2019 Feb;44(2):141-152. doi:10.1016/j.tibs.2018.09.008.

Suzuki T. Regulation of the intestinal barrier by nutrients: the role of tight junctions. Anim Sci J. 2020 Jan-Dec;91(1):e13357. doi:10.1111/asj.13357.

Citi S. The mechanobiology of tight junctions. Biophys Rev. 2019 Oct;11(5):783-793. doi:10.1007/s12551-019-00582-7.

Robles A, Perez Ingles D, Myneedu K, et al. Mast cells are increased in the small intestinal mucosa of patients with irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil. 2019 Dec;31(12):e13718. doi:10.1111/nmo.13718.

Bankole E, Read E, Curtis MA, Neves JF, Garnett JA. The relationship between mucins and ulcerative colitis: a systematic review. J Clin Med. 2021 Apr 30;10(9):1935. doi:10.3390/jcm10091935.

Heitkemper MM, Cain KC, Shulman RJ, et al. Stool and urine trefoil factor 3 levels: associations with symptoms, intestinal permeability, and microbial diversity in irritable bowel syndrome. Benef Microbes. 2018 Apr 25;9(3):345-355. doi:10.3920/BM2017.0059.

Sarink D, Schock H, Johnson T, et al. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort. BMC Cancer. 2018 Oct 22;18(1):1010. doi:10.1186/s12885-018-4887-3.



How to Cite

Dorofeyev, A., Tkach, S., Dyadyk О., & Prikhodko, V. (2022). Features of the mucous barrier in functional bowel diseases and ulcerative colitis. GASTROENTEROLOGY, 56(2), 89–94. https://doi.org/10.22141/2308-2097.56.2.2022.493



Original Researches

Most read articles by the same author(s)

1 2 3 > >>